SLP
Simulations Plus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SLP
Simulations Plus, Inc.
A leading provider in the biosimulation market that provides software and consulting services supporting drug discovery, development, research, and regulatory submissions
Healthcare Technology
07/17/1996
12/31/2007
NASDAQ Stock Exchange
212
08-31
Common stock
800 Park Offices Drive, Suite 401, Research Triangle Park, NC 27709
--
Simulations Plus, Inc., was incorporated in California on July 17, 1996. The company is a global leader and premier supplier in biopharmaceuticals, providing advanced software and consulting services to enhance drug discovery and development, clinical trial operations and commercialization. The Company supports its clients throughout the entire drug development lifecycle, from early detection to clinical development (" R&D "), including clinical operations, to product commercialization. The company serves clients as a strategic partner throughout the drug development lifecycle, providing solutions that integrate scientific software platforms, artificial intelligence-enhanced insights, and expert consulting.
Earnings Call
Q4/2023
Estimate EPS0.18
Actual EPS0.18
Estimate Revenue--
Actual Revenue15.60M
Simulations Plus's Earnings Calls Reveal Contradictions on Renewal Rates, Revenue Growth, and Immunometrics Contributions
Nov 24,2025 01:00
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.25
Actual EPS0.45
Estimate Revenue20.93M
Actual Revenue20.40M
Simulations Plus Q3 2025: Unpacking Contradictions in Software Renewals, Revenue Visibility, and AI Strategies
Jul 14,2025 08:35
Earnings Decrypt
Earnings Decrypt
Q4/2025
Estimate EPS0.12
Actual EPS0.1
Estimate Revenue17.39M
Actual Revenue17.50M
Simulations Plus Q4 2025: Contradictions Emerge on Renewal Rates, AI Pricing, FDA Impact, and Biotech Funding
Dec 03,2025 01:16
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SLP has released its 2025 Q4 earnings. EPS was reported at 0.1, versus the expected 0.12, missing expectations. The chart below visualizes how SLP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SLP has released its 2025 Q4 earnings report, with revenue of 17.46M, reflecting a YoY change of -6.45%, and net profit of -681.00K, showing a YoY change of -180.78%. The Sankey diagram below clearly presents SLP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
